tert-butyl (2S,3S)-4-azido-3-hydroxy-1-phenylbutan-2-ylcarbamate | 1385766-21-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (2S,3S)-4-azido-3-hydroxy-1-phenylbutan-2-ylcarbamate
• 英文别名: tert-butyl N-[(2S,3S)-4-azido-3-hydroxy-1-phenylbutan-2-yl]carbamate
• CAS: 1385766-21-1
• 化学式: C₁₅H₂₂N₄O₃
• 分子量: 306.365
• InChiKey: LECORZARFQSVSF-STQMWFEESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S,3S)-4-azido-3-hydroxy-1-phenylbutan-2-ylcarbamate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 N¹-((2S,3S)-4-azido-3-hydroxy-1-phenylbutan-2-yl)-N³-((R)-1-(4-fluorophenyl)ethyl)-5-(N-methylmethylsulfonamido)isophthalamide
  参考文献：
  名称：

  Discovery of pyrazole as C-terminus of selective BACE1 inhibitors

  摘要：

  We recently discovered and reported dual inhibitor 5 of AChE and BACE1 with N-benzylpiperidine ethyl as C-terminus. Compound 5 showed potent inhibitory activities for BACE1, and could reduce endogenous A beta(1-40) production in APP transgenic mice. In present work, we rapidly identified substituted triazole as the C-terminus of compound 5 by replacing the benzylpiperidine ethyl group with click chemistry and tested these synthesized compounds by in situ screening assay. As revealed by the crystal structures of BACE1 in complex with our triazole compound 12, we found that Pro70 and Thr72 located in the flap region were the critical components for binding with these inhibitors. With the aid of the crystal structure, a new series of five-membered heterocyclic compounds was prepared in order to explore the structure activity relationship (SAR) of this class of molecules. From these efforts, pyrazole was discovered as a novel C-terminus of BACE1 inhibitors. After further modification of pyrazole with variable substituents, compound 37 exhibited good potency in enzyme inhibition assay (IC50 = 0.025 mu M) and compound 33 showed moderate inhibition effects on A beta production of APP transfected HEK293 cells. Moreover, these pyrazole derivatives demonstrated good selectivity versus cathepsin D. Our results indicated that the vicinity of Pro70 and Thr72 might be utilized as a subsite, and the discovered pyrazole derivatives might provide useful hints for developing novel BACE1 inhibitors as anti-AD drugs. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.06.027
• 作为产物：
  描述：

  (1S)-1-(2R)-环氧乙基-2-苯乙基氨基甲酸叔丁酯 在 sodium azide 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 生成 tert-butyl (2S,3S)-4-azido-3-hydroxy-1-phenylbutan-2-ylcarbamate
  参考文献：
  名称：

  WO2008/13834

  摘要：

  公开号：

文献信息

• [EN] 4-ARYL-BUTANE-1,3-DIAMIDES<br/>[FR] 4-ARYLBUTANE-1,3-DIAMIDES
  申请人：NOVARTIS AG

  公开号：WO2010086366A1

  公开（公告）日：2010-08-05

  The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; m free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  这项发明涉及式(I)的化合物，其中取代基如规范中定义；m自由形式或盐形式；其制备，作为药物的用途以及包含它的药物。
• INDOLE COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSIS
  申请人：Kim Soon Ha

  公开号：US20100210647A1

  公开（公告）日：2010-08-19

  The present invention relates to new indole compounds, pharmaceutically acceptable salts or isomers thereof which are useful for the prevention or treatment of cellular necrosis and necrosis-associated diseases. The present invention also relates to a method and a composition for the prevention or treatment of cellular necrosis and necrosis-associated diseases, comprising said indole compounds as an active ingredient.

  本发明涉及新的吲哚化合物，其药学上可接受的盐或异构体，用于预防或治疗细胞坏死和坏死相关疾病。本发明还涉及一种预防或治疗细胞坏死和坏死相关疾病的方法和组合物，该组合物包括所述吲哚化合物作为活性成分。
• 4-ARYL-BUTANE-1,3-DIAMIDES
  申请人：BEHNKE Dirk

  公开号：US20100222396A1

  公开（公告）日：2010-09-02

  The invention relates to compound of the formula I in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  该发明涉及公式I的化合物，其中取代基如规范中所定义；以自由形式或盐形式存在；其制备方法，其作为药物的用途以及包含它的药物。
• WO2008/13834
  申请人：——

  公开号：——

  公开（公告）日：——
• US8222414B2
  申请人：——

  公开号：US8222414B2

  公开（公告）日：2012-07-17